Ribocure Completes RMB 70 Million Acquisition to Increase Stake in Xingborun to 88.17%

Transaction Overview

Acquirer: Ribo Life Science

Seller: Haihe Asymchem Fund

Target Company: Xingborun, a direct non-wholly-owned subsidiary of Ribo Life Science

Transaction Consideration: RMB 70 million, payable in cash

Equity Acquisition Ratio: 25.93%

Announcement Date: June 30, 2026

Reason for the Transaction: This acquisition implements the redemption right mechanism stipulated in the previous capital increase agreement. Upon Ribo Life Science’s expression of its intent to redeem and subsequent approval by the seller, Haihe Asymchem Fund, both parties negotiated and finalized the transaction. Following the completion of the acquisition, Ribo Life Science’s shareholding in Xingborun will increase significantly from approximately 62.24% to approximately 88.17%, further consolidating its absolute control over Xingborun.

AboutXingborun

Public information shows that TianTianjin Xingborun Biopharmaceutical Co., Ltd. was established on August 23, 2017, with its registered address at No. 3 New Zhang Road, West Zone, Tianjin Economic-Technological Development Area. As a subsidiary of Suzhou Ribo Life Science Co., Ltd., the company specializes in the research and development, production, and sales of nucleic acid monomers and related products, with a focus on nucleic acid raw materials—nucleoside/nucleotide monomers and their related products.

Nucleoside monomers are essential raw materials for the preparation of DNA and RNA, widely used in fields such as the production of nucleic acid drugs (including nucleic acid vaccines), gene synthesis, primer synthesis, pesticide manufacturing, and the production of diagnostic and sequencing reagents.

The phosphoramidite monomers developed and manufactured by the company are key raw materials for producing small nucleic acid (siRNA) drugs. Due to high technical barriers, their quality directly impacts the efficacy and safety of the final products;Phosphoramidite monomers and nucleoside raw materials have been used in Ribo Life Science’s siRNA clinical products and in the original research projects of other clients.